Kazia Therapeutics
KZIA
6 hedge funds and large institutions have $293K invested in Kazia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
27% less capital invested
Capital invested by funds: $400K → $293K (-$107K)
33% less funds holding
Funds holding: 9 → 6 (-3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.57K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$272 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $149K | +$2.85K | +21 | +2% |
|
2
Renaissance Technologies
New York
| $83K | – | – | – |
|
|
TW
3
Transform Wealth
Greenwood Village,
Colorado
| $27K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $25K | -$272 | -2 | -0.9% |
|
|
5
UBS Group
Zurich,
Switzerland
| $9K | -$5.57K | -41 | -34% |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $78 | – | – | – |
|
|
7
Acadian Asset Management
Boston,
Massachusetts
| – | -$8K | -48 | Closed |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| – | -$2K | -11 | Closed |
|
KZIA Hedge Fund Activity: Q4 2018 in Review
6 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2018, worth a combined $293K — down 27% from $400K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of KZIA and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $2.85K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $8K sold.
- 6 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2018, down from 9 in Q3 2018.
- Funds reported $293K of Kazia Therapeutics stock for Q4 2018, down 27% quarter-over-quarter.
- 0 funds opened new Kazia Therapeutics positions in Q4 2018 and 3 closed out, a net change of -3 holders.
- The largest Kazia Therapeutics buyer in Q4 2018 was Morgan Stanley, an estimated $2.85K added.
- The largest Kazia Therapeutics seller in Q4 2018 was Acadian Asset Management, an estimated $8K sold.
Based on aggregated 13F filings for Q4 2018.